Zofran Lawsuit Update: Plaintiffs Question Why GSK Hasn’t Faced Stiffer Penalties

April 29, 2016 – – ZofranLegal.com reports that, as plaintiffs learn more about the defendant named in the more than 230 lawsuits, they are beginning to question why the company hasn’t suffered harsher penalties in the past.

These plaintiffs are all alleging that an unborn child developed a birth defect after the mother was prescribed the anti-nausea medication Zofran as a treatment for morning sickness. They also claim that GlaxoSmithKline, the makers of the drug, marketed the drug unlawfully for “off-label” use, failed to inform the medical community of potential side effects, and didn’t perform the necessary safety testing before informing doctors and the public that Zofran was “safe” for pregnant women.

The drug has been available via prescription since 1991. While the U.S. Food and Drug Administration did approve the drug, their label indicates that it should be given to patients who are suffering from nausea and vomiting after undergoing treatments involving chemotherapy, radiation, and anesthesia. The FDA did not approve the drug as a treatment for morning sickness.

Plaintiffs are claiming that the drug caused cleft lip, cleft palate, atrial septal defect, ventricular septal defect, respiratory distress syndrome, ear deformities, and kidney defects.

This isn’t the first time the company has faced a lawsuit regarding one of its drugs. Between the years of 1991 and 2005, the company has paid nearly $8 billion dollars in settlements to the federal government. While this number may seem very high, it pales in comparison to the amount the company has made in profits off of their products. Many have wondered if higher amounts in settlement payments would prevent the company from making decisions which could potentially cause thousands of people harm.

The attorneys at Monheit Law are currently offering complimentary consultations to anyone who believes their unborn child developed a birth defect due to Zofran. For more information, contact Michael Monheit at 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60009600